93 related articles for article (PubMed ID: 9616747)
1. Computer-assisted molecular design for the determination of structure-activity relationships for chemopreventive agents.
Lü HQ; Schmitz U; Niggemann B; Zänker KS
Ann N Y Acad Sci; 1997 Dec; 833():147-53. PubMed ID: 9616747
[No Abstract] [Full Text] [Related]
2. Suppression of the proliferation and migration of oncogenic ras-dependent cell lines, cultured in a three-dimensional collagen matrix, by flavonoid-structured molecules.
Lü HQ; Niggemann B; Zänker KS
J Cancer Res Clin Oncol; 1996; 122(6):335-42. PubMed ID: 8642043
[TBL] [Abstract][Full Text] [Related]
3. A novel class of inhibitors for steroid 5alpha-reductase: synthesis and evaluation of umbelliferone derivatives.
Fan G; Mar W; Park MK; Choi EW; Kim K; Kim S
Bioorg Med Chem Lett; 2001 Sep; 11(17):2361-3. PubMed ID: 11527731
[TBL] [Abstract][Full Text] [Related]
4. KRAS
Cagir A; Azmi AS
Future Med Chem; 2019 May; 11(9):923-925. PubMed ID: 31140867
[No Abstract] [Full Text] [Related]
5. Three-dimensional structure of p21 in the active conformation and analysis of an oncogenic mutant.
Wittinghofer F; Krengel U; John J; Kabsch W; Pai EF
Environ Health Perspect; 1991 Jun; 93():11-5. PubMed ID: 1773783
[TBL] [Abstract][Full Text] [Related]
6. Antitumor and immunomodulatory effect of coumarin and 7-hydroxycoumarin against Sarcoma 180 in mice.
Stefanova TH; Nikolova NJ; Toshkova RA; Neychev HO
J Exp Ther Oncol; 2007; 6(2):107-15. PubMed ID: 17407969
[TBL] [Abstract][Full Text] [Related]
7. HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
Sugita S; Enokida H; Yoshino H; Miyamoto K; Yonemori M; Sakaguchi T; Osako Y; Nakagawa M
Int J Oncol; 2018 Aug; 53(2):725-736. PubMed ID: 29901113
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of guanosine triphosphate hydrolysis by Ras and Ras-GAP proteins as rationalized by ab initio QM/MM simulations.
Grigorenko BL; Nemukhin AV; Shadrina MS; Topol IA; Burt SK
Proteins; 2007 Feb; 66(2):456-66. PubMed ID: 17094109
[TBL] [Abstract][Full Text] [Related]
9. Morphology of ras-transformed cells becomes apparently normal again with tyrosine kinase inhibitors without a decrease in the ras-GTP complex.
Kwon HJ; Yoshida M; Muroya K; Hattori S; Nishida E; Fukui Y; Beppu T; Horinouchi S
J Biochem; 1995 Jul; 118(1):221-8. PubMed ID: 8537316
[TBL] [Abstract][Full Text] [Related]
10. ras effector loop mutations that dissociate p120GAP and neurofibromin interactions.
Stang S; Bottorff D; Stone JC
Mol Carcinog; 1996 Jan; 15(1):64-9. PubMed ID: 8561868
[TBL] [Abstract][Full Text] [Related]
11. Purification of a factor capable of stimulating the guanine nucleotide exchange reaction of ras proteins and its effect on ras-related small molecular mass G proteins.
Huang YK; Kung HF; Kamata T
Proc Natl Acad Sci U S A; 1990 Oct; 87(20):8008-12. PubMed ID: 2172971
[TBL] [Abstract][Full Text] [Related]
12. Direct inhibition of oncogenic KRAS by Bacillus pumilus ribonuclease (binase).
Ilinskaya ON; Singh I; Dudkina E; Ulyanova V; Kayumov A; Barreto G
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1559-67. PubMed ID: 27066977
[TBL] [Abstract][Full Text] [Related]
13. 'Hot spot' amino acid distribution in Ha-ras oncogene product p21: relationship to guanine binding site.
Cosic I; Hearn MT
J Mol Recognit; 1991; 4(2-3):57-62. PubMed ID: 1810347
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of free radical nitric oxide-mediated Ras guanine nucleotide dissociation.
Heo J; Prutzman KC; Mocanu V; Campbell SL
J Mol Biol; 2005 Mar; 346(5):1423-40. PubMed ID: 15713491
[TBL] [Abstract][Full Text] [Related]
15. GTP-binding proteins as oncogenes in human tumors.
McCormick F
Environ Health Perspect; 1991 Jun; 93():17-8. PubMed ID: 1773789
[No Abstract] [Full Text] [Related]
16. Linear free energy relationships in the intrinsic and GTPase activating protein-stimulated guanosine 5'-triphosphate hydrolysis of p21ras.
Schweins T; Geyer M; Kalbitzer HR; Wittinghofer A; Warshel A
Biochemistry; 1996 Nov; 35(45):14225-31. PubMed ID: 8916907
[TBL] [Abstract][Full Text] [Related]
17. Regulators and effectors of ras proteins.
Bollag G; McCormick F
Annu Rev Cell Biol; 1991; 7():601-32. PubMed ID: 1667084
[No Abstract] [Full Text] [Related]
18. A guide to low molecular weight GTPases.
Sanders DA
Cell Growth Differ; 1990 May; 1(5):251-8. PubMed ID: 2150754
[No Abstract] [Full Text] [Related]
19. Combined effect of chemopreventive agent N-(4-hydroxyphenyl) retinamide (4-HPR) and gamma-radiation on bladder cancer cell lines.
Zou C; Wang L; Liebert M; Grossman HB; Lotan R; Wei Q
Int J Oncol; 1998 Nov; 13(5):1037-41. PubMed ID: 9772297
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of p21ras.GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity.
Satoh T; Endo M; Nakafuku M; Akiyama T; Yamamoto T; Kaziro Y
Proc Natl Acad Sci U S A; 1990 Oct; 87(20):7926-9. PubMed ID: 2146678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
